5 Key Takeaways
-
1
Breye Therapeutics raised €67.5 million in a Series A financing round to advance danegaptide for non-proliferative diabetic retinopathy.
-
2
The funding will support a Phase II clinical trial of danegaptide, aimed at clinical proof-of-concept in patients with NPDR.
-
3
Danegaptide is an oral small molecule designed to stabilize retinal vasculature and protect against vascular leakage due to chronic hyperglycemia.
-
4
Breye's Phase Ib study of danegaptide in 2025 showed it was well tolerated and indicated reduced vascular leakage in retinal imaging.
-
5
The financing will also support Breye's pipeline, including an oral P2X7 receptor antagonist for age-related macular degeneration.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
